IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors Meeting Abstract
| Authors: | Aggen, D. H.; McKean, M.; Hoffman-Censits, J. H.; Lakhani, N. J.; Alhalabi, O.; Guancial, E. A.; Bashir, B.; Bowman, I. A.; Tan, A.; Lingaraj, T.; Kim, K.; Timothy, M.; Ortiz-Otero, N.; Bartolini, W.; Kacena, K.; Santillana, S.; Luke, J. J. |
| Abstract Title: | IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400541 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.2599 |
| Notes: | Meeting Abstract: 2599 -- Source: Wos |
